|
SFRS2IP expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.76514400055339E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.95920002443728E-09 |
| Normal-vs-Stage2 |
9.21709999990306E-07 |
| Normal-vs-Stage3 |
1.80579995401331E-10 |
| Normal-vs-Stage4 |
7.34360350307384E-11 |
| Stage1-vs-Stage2 |
6.258000E-01 |
| Stage1-vs-Stage3 |
1.428380E-01 |
| Stage1-vs-Stage4 |
1.948250E-02 |
| Stage2-vs-Stage3 |
5.860000E-01 |
| Stage2-vs-Stage4 |
2.386800E-01 |
| Stage3-vs-Stage4 |
4.006400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.07590047981887E-10 |
| Normal-vs-AfricanAmerican |
9.031000E-04 |
| Normal-vs-Asian |
9.20910000479225E-08 |
| Caucasian-vs-AfricanAmerican |
4.124200E-01 |
| Caucasian-vs-Asian |
6.641800E-01 |
| AfricanAmerican-vs-Asian |
2.794800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.03660413586226E-11 |
| Normal-vs-Female |
1.69000036187583E-10 |
| Male-vs-Female |
2.899800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.04229999578587E-08 |
| Normal-vs-Age(41-60Yrs) |
2.55329979381713E-10 |
| Normal-vs-Age(61-80Yrs) |
1.34749988944804E-10 |
| Normal-vs-Age(81-100Yrs) |
1.798880E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.971800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.168410E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.786400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.639600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.827600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.960000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.448400E-02 |
| Classical-VS-Follicular |
1.704470E-02 |
| Classical-VS-Other |
1.318790E-01 |
| Classical-VS-Normal |
2.55559995387955E-09 |
| Tall-VS-Follicular |
8.752200E-01 |
| Tall-VS-Other |
5.463400E-01 |
| Tall-VS-Normal |
2.36839999945282E-07 |
| Follicular-VS-Other |
5.512200E-01 |
| Follicular-VS-Normal |
2.55550003380733E-09 |
| Other-VS-Normal |
6.373800E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.03446198460733E-12 |
| Normal-vs-N1 |
5.88009996249639E-09 |
| N0-vs-N1 |
5.989800E-01 |
|
|
